Recursion pharmaceuticals: decoding the future of medicine

The emergence of the “TechBio” sector represents a fundamental paradigm shift in the life sciences, moving away from the traditional, hypothesis-driven model of drug discovery toward an industrialized, data-centric approach. At the forefront of this transition is Recursion Pharmaceuticals, a clinical-stage biotechnology company that has spent over a decade building a vertically integrated infrastructure designed to “decode” biology.¹ By treating the discovery of new medicines as a massive search problem across a multi-dimensional map of biological and chemical relationships, the company seeks to address the systemic inefficiencies that have long plagued the pharmaceutical industry—namely, the $90\%$ failure rate of drugs in clinical development and the multi-billion-dollar cost of bringing a single therapy to market.²

Corporate Overview and the Evolution of the TechBio Paradigm

Recursion Pharmaceuticals was founded in 2013 on a vision that cellular morphology, captured through high-resolution microscopy and analyzed via artificial intelligence, could reveal latent biological insights that human intuition might overlook.² Headquartered in Salt Lake City, Utah, the company has transformed from a phenotypic screening startup into a global organization with a workforce of approximately 800 “Recursionauts” and research hubs in Montréal, New York, London, and the Oxford area.⁴ This growth has been fueled by a combination of internal platform development and an aggressive mergers and acquisitions strategy aimed at creating an end-to-end “full-stack” TechBio platform.⁶

The company’s mission is to decode biology to radically improve lives.¹ This mission is operationalized through the Recursion Operating System (OS), an integrated suite of technologies that combines automated wet-lab experimentation with massive computational scale.⁸ Unlike traditional pharmaceutical companies that often focus on a single disease or target based on a specific biological hypothesis, Recursion builds “Maps of Biology” that allow for the unbiased exploration of disease drivers across thousands of genes and chemical perturbations simultaneously.³

Strategic Leadership and Governance Evolution

Recursion is currently navigating a pivotal leadership transition designed to move the organization from its foundational platform-building phase into a phase characterized by clinical execution and commercialization.¹⁰ On November 5, 2025, the company announced that Co-Founder and CEO Chris Gibson, Ph.D., will transition to the role of Chairman of the Board of Directors and Executive Advisor, effective January 1, 2026.⁵ Dr. Gibson’s decade-long tenure has been marked by the assembly of the company’s core technological assets and its high-profile partnerships with industry titans.³

Succeeding Dr. Gibson is Dr. Najat Khan, who currently serves as Chief R&D and Chief Commercial Officer.¹¹ Dr. Khan joined Recursion in 2024 following a distinguished career at Johnson & Johnson, where she served as Chief Data Science Officer and Global Head of Strategy for R&D.¹² Her appointment reflects a clear strategic intent to prioritize the translation of platform-derived insights into a robust pipeline of late-stage clinical assets.⁵ Dr. Khan’s experience in scaling AI across massive R&D portfolios is viewed as critical for the next phase of Recursion’s growth, particularly as it integrates the capabilities of its recent merger with Exscientia.⁶

The governance structure is further supported by a Board of Directors that bridges the divide between deep-tech venture capital and traditional pharmaceutical expertise.⁴ Robert Hershberg, M.D., Ph.D., a veteran of Celgene and Bristol-Myers Squibb, will transition from his current role as Chairman to Vice-Chairman and Lead Independent Director, ensuring continuity in strategic oversight.⁵ Other board members, such as Zachary Bogue of Data Collective (DCVC) and Blake Borgeson, provide expertise in scaling deep-tech enterprises and bioinformatics, respectively.¹⁴

Key Leadership Transition	Current Role	Future Role (Jan 1, 2026)	Primary Focus
Chris Gibson, Ph.D.	CEO & Co-Founder	Chairman & Executive Advisor	Long-term strategy and TechBio advocacy ⁵
Najat Khan, Ph.D.	Chief R&D & Commercial Officer	CEO & President	Clinical execution and commercialization ¹¹
Robert Hershberg, M.D., Ph.D.	Chairman	Vice-Chairman & Lead Independent Director	Governance and strategic oversight ⁵
David Hallett, Ph.D.	Chief Scientific Officer	Chief Scientific Officer	Research innovation and platform science ⁴
Ben Taylor	CFO	CFO & President Recursion UK	Financial sustainability and synergies ⁴

The Technological Core: The Recursion Operating System (OS)

The Recursion Operating System (OS) is the proprietary technological engine that distinguishes the company from both traditional biotech and first-generation AI drug discovery firms.¹ It is structured as an iterative loop—a “flywheel”—where data generated in physical labs informs digital models, which in turn direct the next set of physical experiments.² This “Atoms and Bits” strategy is designed to industrialize the discovery process by removing human bias and scaling experimental throughput to levels previously unimaginable in biological research.⁶

Physical Infrastructure: Automated Laboratories and Multi-Omic Scale

The physical component of the OS resides in Recursion’s automated wet laboratories, which are among the most sophisticated in the biopharmaceutical industry.⁸ These labs utilize robotics and computer vision to process up to 2.2 million samples per week.⁸ The scale is achieved through miniaturization, with experiments typically conducted in 1536-well plates, where each “well” represents a unique biological condition or treatment.⁸

Recursion’s data generation capabilities span multiple “layers” of biology, creating a high-resolution view of how diseases disrupt cellular function and how drugs might restore it.⁸

Phenomics: This remains the company’s foundational data layer.³ By using high-content microscopes to take millions of brightfield and fluorescent images of cells, Recursion captures the “morphology”—the shape and structure—of the cell.³ The company currently generates up to 16.2 million images per week, totaling over 135 terabytes of visual data.¹³ These images are then “embedded” into a mathematical space where AI can identify “disease signatures”—distinct patterns of cellular disruption.³
Transcriptomics (Trekseq): In 2023, Recursion launched Trekseq, a high-throughput transcriptomics platform that measures gene expression (mRNA levels) at scale.⁸ To date, the company has generated over 1.6 million individual transcriptomes, including the world’s first genome-scale CRISPR knockout map in primary human cells.¹³ This allows the company to see not just how a cell looks, but which genes it is turning “on” or “off” in response to a perturbation.⁸
InVivomics: To bridge the gap between cell-based models and human trials, Recursion has developed “InVivomics,” which uses digital biomarkers and computer vision to monitor animal models.² The company has collected over 1 million hours of video data and digital biomarkers, allowing for a more nuanced understanding of drug effects on behavior and physiology in vivo.¹³
Proteomics and ADME: Following the integration of Exscientia and previous acquisitions, Recursion has incorporated proteomics (protein levels) and ADME (absorption, distribution, metabolism, and excretion) data into its discovery cycles.⁸ This ensures that candidates are optimized not just for biological activity, but for the chemical properties required to become a viable medicine.⁸

Digital Infrastructure: Supercomputing and AI Foundation Models

The massive volume of data—now exceeding 65 petabytes—requires unprecedented computational power to process.² Recursion has addressed this by building BioHive-2, an NVIDIA-powered supercomputer that is currently the most powerful wholly-owned system in the biopharmaceutical industry.⁹

BioHive-2 is an NVIDIA DGX SuperPOD consisting of 63 DGX H100 systems with a total of 504 GPUs.⁹ It delivers approximately 2 exaflops of AI performance, making it nearly five times faster than its predecessor, BioHive-1.¹⁹ This computational horsepower allows Recursion to train “foundation models”—large-scale AI models that learn the fundamental rules of biology and chemistry.⁹

Foundation Model	Primary Capability	Impact on Discovery
Phenom-1 / Phenom-2	Image feature extraction	Converts raw cellular images into meaningful biological representations ⁹
MolGPS	Molecular property prediction	Maps chemical structures to biological activities and ADME properties ¹³
Boltz-2	Binding affinity prediction	Predicts how strongly a drug binds to its target with physics-level accuracy at $1,000\times$ speed ²⁰
MolPhenix	Predictive phenomics	Learns and predicts the effects of novel molecules on cellular phenotype ⁸

A unique element of the digital OS is LOWE (Large Language Model-Orchestrated Workflow Engine), an AI software that provides a natural language interface for scientists.²² LOWE can orchestrate both wet-lab and dry-lab components of the OS, allowing a scientist to describe an experiment in plain English and have the AI handle the complex logistics of plate seeding, CRISPR editing, imaging, and data analysis.¹⁹ This essentially democratizes the use of the company’s massive infrastructure, turning it into a scalable tool for human researchers.²²

Strategic Acquisitions and the Full-Stack Vision

Recursion’s growth has been accelerated by a series of strategic acquisitions designed to fill critical gaps in its technological stack, particularly in the realm of chemistry.¹⁸ While the early years of the company were focused on biology exploration and target identification, the recent focus has shifted toward precision design and automated synthesis.⁷

Digital Chemistry and Generative AI: Cyclica and Valence

In May 2023, Recursion acquired Cyclica and Valence Discovery for an aggregate price of approximately $\$87.5$ million in stock.¹⁸ Cyclica contributed the “MatchMaker” platform, an AI engine capable of predicting the interactions between small molecules and the entire human proteome.²³ This technology allowed Recursion to predict protein targets for approximately 36 billion chemical compounds in just one week—a task that would have taken traditional methods a century.²⁶

Valence Discovery, based in Montréal, brought expertise in “low-data learning,” which is critical when developing molecules for novel biological targets where experimental data is sparse.²³ The Valence team now operates as “Valence Labs,” a semi-autonomous research hub within Recursion focused on the frontier of molecular machine learning.²²

The Exscientia Merger: Achieving Vertical Integration

The most significant strategic move in Recursion’s history was the merger with Exscientia, finalized in November 2024.⁶ This transaction combined Recursion’s biology-first platform with Exscientia’s chemistry-first platform, creating a “vertically-integrated” TechBio entity.⁶ Exscientia contributed the “Centaur” platform for precision chemistry design and an automated small molecule synthesis platform, which allows the company to physically manufacture the molecules its AI designs.⁷

The merger is expected to yield over $\$100$ million in annual synergies, with the majority of the run-rate savings achieved in 2025.⁷ Beyond cost savings, the primary value of the merger lies in the integration of the “Design-Make-Test-Learn” cycle.⁶ Recursion can now identify a novel target (Test), design a precision molecule for it (Design), synthesize that molecule in-house (Make), and then feed the results back into its models to improve future predictions (Learn).⁶

Synergy Driver	Metric / Milestone	Strategic Importance
Operational Synergies	$>\$100$M annual run-rate	Extends cash runway and reduces duplication ⁷
Technical Integration	$25\%$ improved tractability	Higher quality of AI-generated compounds ¹³
Pipeline Breadth	$>10$ clinical programs	Multiple “shots on goal” for platform validation ⁶
Talent Moat	$\sim800$ employees	Concentration of top AI and life-science talent ⁴

Revenue Structure and the Partnership Ecosystem

Recursion’s business model is a hybrid of internal drug development and high-value strategic partnerships.¹⁵ This approach allows the company to generate near-term non-dilutive capital through collaboration fees and milestones while retaining the long-term upside of a proprietary pipeline.¹⁵ As of late 2025, Recursion has achieved more than $\$500$ million in cumulative upfront and milestone payments from its partners, a figure that underscores the industry’s validation of its approach.¹⁰

Strategic Pharmaceutical Collaborations

The core of Recursion’s current revenue stream is derived from multi-year, multi-target collaborations with some of the world’s largest pharmaceutical companies.¹⁰ These partnerships typically involve Recursion using its OS to identify novel targets or molecules for specific therapeutic areas of interest to the partner.¹⁰

Roche and Genentech: This is Recursion’s largest and most significant partnership—a 10+ year collaboration focused on neuroscience and gastrointestinal (GI) oncology.¹⁰ The partnership has a potential value of over $\$30$ billion in milestones plus royalties.⁶ To date, Recursion has received $\$213$ million from this collaboration, including a $\$30$ million milestone in Q3 2025 for the delivery of a whole-genome phenotypic map of microglial immune cells.¹⁰ Roche and Genentech have already optioned their first program in GI oncology, highlighting the partnership’s transition from mapping to active discovery.¹⁰
Sanofi: Focused on oncology and immunology, this partnership covers up to 15 programs.¹⁰ Each individual program has the potential for over $\$300$ million in milestone payments.¹⁰ Recursion has received $\$130$ million from Sanofi to date, and the partnership reached its fourth major discovery milestone in mid-2025.¹⁰ Sanofi has also begun leveraging “Recursion OS 2.0,” which incorporates phenomics and multimodal data, to identify new program opportunities.²¹
Bayer: Initially focused on fibrotic diseases, the partnership was expanded to include precision oncology programs.²¹ Bayer has achieved several lead-series milestones and has become the first beta-user of the LOWE software platform, integrating Recursion’s AI workflow engine into their internal R&D infrastructure.¹³

Technology and Data Monetization

Beyond traditional R&D collaborations, Recursion is exploring new ways to monetize its technological stack.¹⁵

Software Licensing: The company generates revenue by licensing its AI platforms, such as LOWE, to other drug makers.²⁹ In 2023, licensing revenue reached approximately $\$12.7$ million.²⁹ This model is similar to that of Schrödinger, providing a more stable, recurring revenue stream that is less dependent on the binary outcomes of clinical trials.¹⁵
AI Model Distribution: In collaboration with NVIDIA, Recursion intends to optimize and distribute its foundation models to the broader biotechnology industry using NVIDIA cloud services.³² This includes possible commercial licensing on BioNeMo, NVIDIA’s cloud service for drug discovery.³² The release of the Boltz-2 model under an MIT license, while open-source, drives industry adoption and positions Recursion as the central “hub” for biological AI, with enterprise-grade deployments requiring NVIDIA AI Enterprise licenses.²⁰

Revenue Component	Source of Capital	Strategic Value
Upfront Payments	New partnerships	Initial non-dilutive funding and validation ²¹
R&D Milestones	Success-based mapping / discovery	Continued capital as programs progress ¹⁰
Licensing Fees	Software (LOWE, etc.)	Recurring, software-like revenue stream ¹⁵
Clinical Milestones	Phase 1, 2, 3 entries	High-value payments for clinical validation ⁶
Royalties	Net sales of approved drugs	Long-term, high-margin passive income ⁶

The Therapeutic Pipeline: Clinical Stages and Strategic Focus

The ultimate validation of the Recursion OS lies in its internal therapeutic pipeline.¹¹ The company has built a diverse portfolio focusing on oncology and rare diseases, areas where phenotypic screening and precision design are particularly effective.² Following the Exscientia merger, the combined company boasts more than 10 clinical and preclinical programs.⁶

Rare Diseases: Leveraging Monogenic Models

Recursion’s rare disease programs often focus on monogenic disorders—conditions caused by a single gene mutation—which can be easily modeled on the platform using CRISPR knockouts.⁸

REC-4881 (MEK1/2 Inhibitor): This is the company’s lead asset, currently in Phase 2 for Familial Adenomatous Polyposis (FAP).¹ FAP is a rare genetic condition where patients develop hundreds of colorectal polyps, often leading to cancer at a young age.³³ In December 2025, Recursion reported positive Phase 1b/2 results from the TUPELO trial, showing rapid and durable reductions in polyp burden.¹ The program has received Fast Track and Orphan Drug designations.³³
REC-102 (ENPP1 Inhibitor): Targeting Hypophosphatasia (HPP), a rare genetic disorder characterized by impaired bone mineralization.³³ Recursion recently consolidated full rights to this program.⁸ Preclinical results in 2025 showed that oral administration of REC-102 significantly reduced plasma inorganic pyrophosphate (PPi) levels and improved bone mineralization in mouse models.³³ A Phase 1 trial initiation is expected in the second half of 2026.¹⁰

Oncology: Targeting Precision and Vulnerability

The oncology pipeline focuses on first-in-class and best-in-class molecules that target specific genetic drivers or biological pathways.³³

REC-617 (CDK7 Inhibitor): A selective, oral CDK7 inhibitor for multiple advanced solid tumors.¹⁷ Currently in Phase 1/2, this candidate is designed for high selectivity to avoid the toxicities that have plagued earlier CDK inhibitors.¹⁷
REC-1245 (RBM39 Degrader): A novel degrader of RBM39, a target that mimics the biological effect of CDK12 loss.¹⁷ It is being developed for biomarker-enriched solid tumors and lymphoma.³³ Phase 1 safety and PK data are expected in 1H 2026.¹⁰
REC-3565 (MALT1 Inhibitor): Developed for relapsed or refractory B-cell lymphomas.² This candidate entered Phase 1 in late 2024 and is designed to minimize side effects like hyperbilirubinemia.²
REC-7735 (PI3K$\alpha$ H1047R Inhibitor): A mutant-selective inhibitor for breast cancer.³³ By specifically targeting the H1047R mutation while sparing the wild-type protein, the company hopes to avoid the hyperglycemia that limits the use of current PI3K inhibitors.³³ Phase 1 is expected to begin in 2H 2026.¹⁰

Pipeline Asset	Target	Disease Area	Clinical Phase	Key Catalyst
REC-4881	MEK1/2	Familial Adenomatous Polyposis	Phase 2	Full TUPELO data expected H1 2026 ¹
REC-617	CDK7	Advanced Solid Tumors	Phase 1/2	Safety/Efficacy data expected 2025 ¹³
REC-1245	RBM39	Biomarker-enriched tumors	Phase 1	PK/Safety data in 1H 2026 ¹⁰
REC-3565	MALT1	B-cell Lymphomas	Phase 1	Safety data in 1H 2027 ¹⁰
REC-102	ENPP1	Hypophosphatasia	Preclinical	Phase 1 entry in 2H 2026 ¹⁰
REC-7735	PI3K$\alpha$	HER2- HR+ Breast Cancer	Preclinical	Phase 1 entry in 2H 2026 ¹⁰

Financial Analysis and Operational Efficiency

Recursion’s financial position reflects its status as a high-growth “TechBio” company that is heavily reinvesting its capital into platform expansion and clinical trials.¹⁵ While the company remains pre-profitable, its low debt levels and strategic capital raises have provided a multi-year cash runway.³⁵

Cash Position and Funding Strategy

As of October 9, 2025, Recursion reported cash and cash equivalents of approximately $\$785$ million.¹⁰ This includes $\$387.5$ million in net proceeds raised through an At-the-Market (ATM) facility during the third and fourth quarters of 2025.¹⁰ Management anticipates that this cash position will support operations through the fourth quarter of 2027, providing a comfortable buffer to achieve several key clinical readouts.¹⁰

The company’s approach to debt is notably conservative.³⁵ Total debt sits at approximately $\$ 82.37$ million, which is minimal compared to its $\$1.4$ billion in total assets.³⁵ The debt-to-equity (D/E) ratio is a mere 0.08, reflecting a deliberate choice to fund growth primarily through equity and milestone payments rather than leverage.³⁵

Revenue Trends and Operational Burn

Revenue is currently characterized by the timing of large milestone payments.³⁵ For example, Q3 2025 revenue was $\$5.2$ million, a significant decrease from $\$26.1$ million in Q3 2024, purely due to the timing of a large Roche milestone that was recognized in the prior year.¹⁰ On a trailing twelve-month (TTM) basis, revenue stood at $\$43.69$ million.³⁵

Financial Metric (TTM Sep 30, 2025)	Amount (USD)	Implication
Total Revenue	$\$ 43.69$ Million	Fluctuates based on milestone timing ³⁵
Research & Development (R&D)	$\$ 521.8$ Million	High investment in platform and pipeline ¹⁰
General & Administrative (G&A)	$\$ 172.5$ Million	Includes integration costs of Exscientia ¹⁰
Net Loss	$\$ 715.5$ Million	Typical for clinical-stage biotech ³⁵
Operating Cash Burn	$\sim \$ 325$ Million	Nine-month burn for 2025 ¹⁰

Operational efficiency is a key long-term goal.⁶ The company has noted that its AI-enabled methods can advance a program from target identification to IND-enabling studies in less than 18 months, compared to an industry average of 42 months.¹⁷ The $\$ 100$ million in expected synergies from the Exscientia merger will further refine this cost structure.⁷

Growth Strategy and Opportunity Factors

Recursion’s growth strategy is predicated on three pillars: clinical proof-of-concept, partnership expansion, and technological commoditization.¹¹

Pillar 1: Clinical Proof and Pipeline Maturity

The most immediate catalyst for value creation is the successful clinical development of its internal programs.¹⁵ As REC-4881 and REC-617 progress toward pivotal trials, Recursion will move from being a “platform story” to a “product story”.¹¹ The recent positive data in FAP is a critical step in this direction, providing the first clear evidence that an AI-discovered molecule can achieve meaningful clinical activity in humans.¹

Pillar 2: The Partnership “Flywheel”

Every successful program discovered for a partner like Roche or Sanofi serves as a dual catalyst: it provides non-dilutive capital to Recursion and validates the OS for future partners.⁶ With the potential for over $\$20$ billion in milestones across its current partnership portfolio, the company has a massive “shadow pipeline” that could generate significant revenue for decades without additional R&D spend from Recursion itself.⁶

Pillar 3: Industrializing and Simulating Biology

Long-term, Recursion aims to move beyond physical experimentation toward large-scale biological simulation.⁶ By building “virtual cells,” the company hopes to execute “clinical trials at scale” in silico, identifying which patient populations are most likely to respond to a drug before a single human is dosed.³ This “ClinTech” strategy—integrating real-world patient data from partners like Tempus and Helix—is designed to further reduce the risk and cost of drug development.²

Risk Factors and Competitive Landscape

Despite its significant advantages, Recursion faces the same inherent risks as any biotechnology firm, along with unique risks associated with its technology-heavy approach.¹⁵

Clinical Failure: The primary risk is the binary nature of clinical trials.¹⁵ If lead assets like REC-4881 fail in later stages, it would cast doubt on the effectiveness of the entire platform.¹⁵ Recursion has already experienced the discontinuation of programs like REC-994 and REC-2282 following strategic reviews and unfavorable mid-stage results.³⁴
Technological Validation: While AI is promising, its ability to consistently outperform traditional methods over the long run has not yet been definitively proven through a commercialized drug.¹⁵
Competition: Recursion faces intense competition from other AI-biotech firms such as Schrödinger, Relay Therapeutics, and Absci, as well as from large pharmaceutical companies that are increasingly building their own internal AI capabilities.³¹
Funding and Dilution: Given the high cash burn, the company may need to raise additional capital before achieving profitability, which could lead to shareholder dilution.¹⁵

Conclusion and Strategic Outlook

Recursion Pharmaceuticals is arguably the most ambitious company in the TechBio space, having built a proprietary ecosystem that spans from genome-scale biological mapping to precision chemical synthesis.¹ Its ability to generate one of the world’s largest biological and chemical datasets, combined with the computational power of BioHive-2, provides a technical moat that is difficult for competitors to replicate.²

The upcoming leadership transition to Dr. Najat Khan signals a strategic pivot toward execution and commercialization.⁵ With a robust cash runway, a validated partnership strategy, and a pipeline reaching critical clinical milestones, Recursion is positioned to prove that the industrialization of drug discovery is not just a technological possibility, but a commercial necessity.⁶ While the risks associated with drug development remain significant, the potential for Recursion to revolutionize how medicines are discovered and developed makes it a cornerstone of the next generation of biotechnology.³

본 글은 정보제공이 목적이며, 투자를 권유하려는 목적이 아닙니다.

Works cited

Recursion Pharmaceuticals, Inc., accessed December 21, 2025, https://ir.recursion.com/
Recursion: Pioneering AI Drug Discovery, accessed December 21, 2025, https://www.recursion.com/
Company Profile: Recursion | pharmaphorum, accessed December 21, 2025, https://pharmaphorum.com/rd/company-profile-recursion
Meet our Team – Recursion, accessed December 21, 2025, https://www.recursion.com/team
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth – GlobeNewswire, accessed December 21, 2025, https://www.globenewswire.com/news-release/2025/11/05/3181227/0/en/Recursion-Announces-CEO-Transition-Plan-to-Drive-Next-Phase-of-Growth.html
Recursion and Exscientia, two … – Recursion Pharmaceuticals, Inc., accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space/
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-enter-definitive-agreement-create/
Recursion OS: The AI platform to industrialize drug discovery, accessed December 21, 2025, https://www.recursion.com/platform
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-announces-completion-nvidia-powered-biohive-2-largest/
Recursion Reports Third Quarter … – Recursion Pharmaceuticals, Inc., accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-reports-third-quarter-2025-financial-results-and/
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-announces-ceo-transition-plan-drive-next-phase-growth/
Recursion Announces CEO Transition Plan to Drive Next Phase of …, accessed December 21, 2025, https://ir.recursion.com/node/11996/pdf
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-provides-business-updates-and-reports-fourth-quarter-2/
Board of Directors – Recursion Pharmaceuticals, Inc., accessed December 21, 2025, https://ir.recursion.com/governance/board-of-directors/
Recursion Pharmaceuticals: The AI Drug Discovery Play – Nasdaq, accessed December 21, 2025, https://www.nasdaq.com/articles/recursion-pharmaceuticals-ai-drug-discovery-play
NVIDIA and Recursion dish on AI-driven chip and drug design, accessed December 21, 2025, https://www.drugdiscoverytrends.com/nvidia-and-recursions-candid-conversation-on-ais-next-big-leap-in-drug-discovery/
Big tech meets biotech: Recursion and the AI gold rush in pharma, accessed December 21, 2025, https://www.pharmaceutical-technology.com/analyst-comment/big-tech-meets-biotech-recursion-ai-gold-rush-pharma/
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results, accessed December 21, 2025, https://ir.recursion.com/node/8376/pdf
Drug Discovery, STAT! NVIDIA, Recursion Speed Pharma R&D With AI Supercomputer, accessed December 21, 2025, https://blogs.nvidia.com/blog/drug-discovery-recursion-supercomputer/
Recursion and NVIDIA Build the Most Powerful Supercomputer in …, accessed December 21, 2025, https://www.nvidia.com/en-us/customer-stories/powerful-supercomputer-in-the-pharmaceutical-industry/
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-reports-second-quarter-2025-financial-results-and/
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference, accessed December 21, 2025, https://ir.recursion.com/node/9451/pdf
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster/
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-provides-business-updates-and-reports-second-quarter-1/
Form 8-K for Recursion Pharmaceuticals INC filed 05/08/2023, accessed December 21, 2025, https://ir.recursion.com/static-files/e11795b6-6a65-42c0-8b0e-2fb738c21942
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-bridges-protein-and-chemical-space-massive-protein/
Recursion to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities – Global Genes, accessed December 21, 2025, https://globalgenes.org/raredaily/recursion-to-acquire-cyclica-and-valence-to-bolster-chemistry-and-generative-ai-capabilities/
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-provides-business-updates-and-reports-first-quarter-0/
Recursion Pharmaceuticals, Inc. (RXRX): Business Model Canvas – DCFmodeling.com, accessed December 21, 2025, https://dcfmodeling.com/products/rxrx-business-model-canvas
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals | The Motley Fool, accessed December 21, 2025, https://www.fool.com/investing/2023/07/18/better-ai-biotech-stock-schrodinger-vs-recursion/
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? – Nasdaq, accessed December 21, 2025, https://www.nasdaq.com/articles/rxrx-vs-rlay-which-precision-biotech-stock-better-bet-now
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery, accessed December 21, 2025, https://ir.recursion.com/news-releases/news-release-details/recursion-announces-collaboration-and-50-million-investment/
Scientific Materials – Research for AI in BioTech and Healthcare, accessed December 21, 2025, https://www.recursion.com/science
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? – May 27, 2025 – Zacks Investment Research, accessed December 21, 2025, https://www.zacks.com/stock/news/2477764/rxrx-vs-sdgr-which-ai-powered-drug-discovery-stock-has-more-upside
Breaking Down Recursion Pharmaceuticals, Inc. (RXRX) Financial Health: Key Insights for Investors – DCFmodeling.com, accessed December 21, 2025, https://dcfmodeling.com/blogs/health/rxrx-financial-health
Recursion 10-Q: Revenue Up, Cash Burn High Post-Exscientia Deal, accessed December 21, 2025, https://www.stocktitan.net/sec-filings/RXRX/10-q-recursion-pharmaceuticals-inc-quarterly-earnings-report-8a41abe2b332.html
Can Recursion Pharmaceuticals’ Strategic Deals Fuel Long-Term Growth? | Nasdaq, accessed December 21, 2025, https://www.nasdaq.com/articles/can-recursion-pharmaceuticals-strategic-deals-fuel-long-term-growth